BCAX Stock Summary and Trading Ideas (Bicara Therapeutics | NASDAQ:BCAX)

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

Bicara Therapeutics trades on the NASDAQ stock market under the symbol BCAX.

As of October 28, 2026, BCAX stock price declined to $9.76 with 15,050,810 million shares trading.

BCAX has a beta of 0.80, meaning it tends to be less sensitive to market movements. BCAX has a correlation of 0.03 to the broad based SPY ETF.

BCAX has a market cap of $645.85 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that BCAX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

BCAX has underperformed the market in the last year with a price return of -42.6% while the SPY ETF gained +13.8%. BCAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -64.9% and -43.7%, respectively, while the SPY returned +4.8% and -0.7%, respectively.

BCAX support price is $16.84 and resistance is $18.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAX shares will trade within this expected range on the day.